$HALB NFL Retired Players Association Endorses Hal
Post# of 630
https://www.newsfilecorp.com/release/132805
Jackson Center, Pennsylvania--(Newsfile Corp. - August 4, 2022) - Halberd Corporation (OTC Pink: HALB) has received a letter of endorsement from Carl Eller, President of the NFL Retired Players Association (NFL RPA), for Halberd's research work in the development of treatments for Traumatic Brain Injury (TBI)/chronic traumatic encephalopathy (CTE) sustained by current and retired players. Traumatic brain injuries often progress to neurodegenerative diseases, such as PTSD, Alzheimer's Disease, Parkinson's Disease, Epilepsy and suicide ideation.
The letter of endorsement from the NFL RPA comes as a result of Halberd's recent accomplishments demonstrating in-vitro elimination from cerebrospinal fluid (CSF) of multiple key inflammatory cytokines associated with head trauma and many neurodegenerative diseases. Carl Eller has spent the past two years as a consultant to Halberd, following and reviewing Halberd's development progress towards eliminating excitatory neurotransmitters (inflammatory antigens) resulting from head injuries.
Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist commented, "We are thrilled to have received this letter of endorsement by an organization which has such a strong interest in finding a solution to the consequences of traumatic brain injury. It is wonderful to finally see recognition of the work we have diligently performed at the universities by our very distinguished scientists. I believe that precisely eradicating the causative factors of TBI in cerebrospinal fluid, through the HALB methodology, will greatly reduce morbidity in these patients."
William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "We would like to thank Carl Eller for this bold statement in recognition of our efforts in treating the effects of brain trauma. We look forward to support from other contact sports organizations and the military as we continue our development of our breakthrough medical technology."